Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2026-04-06 16:04:26 ET · period of report 2026-04-02 · accession 0001439222-26-000057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-06 16:04 | 2026-04-02 | AGIO | Goff Brian | CEO, Dir | M - OptEx | $0.00 | +39.0K | 191.1K | +26% | $0 |
| DMT | 2026-04-06 16:04 | 2026-04-02 | AGIO | Goff Brian | CEO, Dir | S - Sale+OE | $34.71 | -19.1K | 184.5K | -9% | -$661.9K |
| DMT | 2026-04-06 16:04 | 2026-04-02 | AGIO | Goff Brian | CEO, Dir | M - OptEx | $0.00 | -39.0K | 40.5K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2026-04-02 | M | A | 25,528 | $0.00 | 190,076 | D | — | — | |
| 2 | Common | Common stock | 2026-04-02 | S | D | 12,472 | $34.71 | 177,604 | D | — | — | (F1) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated August 8, 2022. |
| 3 | Common | Common stock | 2026-04-02 | M | A | 13,500 | $0.00 | 191,104 | D | — | — | |
| 4 | Common | Common stock | 2026-04-02 | S | D | 6,596 | $34.71 | 184,508 | D | — | — | (F2) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024. |
| 5 | Derivative | Performance share units | 2026-04-02 | M | D | 25,528 | $0.00 | 0 | D | — · — to — | 25,528 Common stock | (F3) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F4) The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested. (F4) The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| 6 | Derivative | Performance share units | 2026-04-02 | M | D | 13,500 | $0.00 | 40,500 | D | — · — to — | 13,500 Common stock | (F3) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F5) The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. (F5) The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |